AdventHealth to Implement Research to Combat Antibiotic Resistance in Kids

AdventHealth is accelerating the use of research-backed best practices for treating pediatric respiratory infections to combat antibiotic resistance and improve patient outcomes.

Two critical challenges in health care are converging: the more than decade delay in the adoption of new research into clinical practice and the growing threat of antimicrobial resistance (AMR) caused by antibiotic overuse.

This delay, along with the rise of drug-resistant infections, puts patients – especially children – at higher risk. With $2.5 million in funding from the Patient-Centered Outcomes Research Institute (PCORI), AdventHealth is fast-tracking research-backed practices to treat acute respiratory tract infections (ARTI), one of the most common pediatric health concerns.

The Growing Threat of Antimicrobial Resistance

The overuse and misuse of antibiotics have led to an alarming global issue – antimicrobial resistance. The recent discussions at the United Nations General Assembly underscore the urgency of tackling AMR, which jeopardizes modern medicine’s ability to treat common infections and is projected to cause 39 million deaths between now and 2050.

AdventHealth’s project will implement findings from a PCORI-funded patient-centered comparative clinical effectiveness research study demonstrating that narrow-spectrum antibiotics were as effective as broad-spectrum antibiotics in treating acute respiratory tract infections like ear infections, sinusitis and sore throats among children, with fewer side effects.

“Antibiotic overuse is not just a global issue, it’s a personal one,” said Dr. Jeffrey Kuhlman, chief quality and safety officer for AdventHealth. “Every unnecessary prescription puts children at risk for adverse side effects and diminishes the future effectiveness of life-saving medications.”

Bridging the Research-to-Practice Gap

AdventHealth is one of 40 health systems nationwide selected by PCORI to participate in the Health Systems Implementation Initiative (HSII). This partnership will accelerate the adoption of evidence-based medical practices into patient care – reducing the typical 17-year gap between research publication and widespread clinical use.

“This PCORI funding award will support AdventHealth to promote antibiotic stewardship for children with acute respiratory tract infections,” said PCORI Executive Director Nakela L. Cook, MD, MPH. “This project exemplifies PCORI's commitment to advancing the uptake of evidence into health care delivery settings to enable parents, caregivers and clinicians to make informed health care decisions and improve care delivery and health outcomes. We look forward to following the project’s progress and collaborating with AdventHealth to share its results.”

A Shared Commitment to Better Outcomes

“This partnership with PCORI is one of the many ways we ensure our care is based on the best medical intelligence available, leading to the best patient outcomes possible,” added Dr. Kuhlman. “By incorporating the latest research directly into our care practices, we are shaping a future where medical discoveries rapidly reach the frontlines of patient care.”

Read more about this effort on the PCORI website.

Recent News

12 items. To interact with these items, press Control-Option-Shift-Right Arrow. These items are in a slider. To advance slider forward, press Shift-Command-Right Arrow. To advance slider backward, press Shift-Command-Left Arrow.
News
New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma

AdventHealth Clinical Research Unit (CRU) Executive Director and Medical Director of Genitourinary Oncology Guru Sonpavde, MD, co-authored an article on the AMBASSADOR Phase III clinical trial results...

Read Article about "New Research Published in New England Journal of Medicine Finds That Adjuvant Pembrolizumab Extends Disease-Free Survival in Muscle-Invasive Urothelial Carcinoma"
News
AdventHealth Involved in Research to Evaluate First Potential Disease-Modifying Treatment for Epileptic Patients with Dravet Syndrome

Under the leadership of principal investigator Ki Hyeong Lee, MD, MS, medical director of AdventHealth for Children’s pediatric epilepsy center in Orlando, AdventHealth Orlando has been one of two...

Read Article about "AdventHealth Involved in Research to Evaluate First Potential Disease-Modifying Treatment for Epileptic Patients with Dravet Syndrome "
News
AdventHealth for Children Collaborating with n-Lorem Foundation to Provide Personalized Treatments to Patients with Nano-rare Genetic Diseases

The n-Lorem Foundation recently selected AdventHealth for Children in Orlando as one of the first institutions in Florida to collaborate with providing personalized antisense oligonucleotide (ASO)...

Read Article about "AdventHealth for Children Collaborating with n-Lorem Foundation to Provide Personalized Treatments to Patients with Nano-rare Genetic Diseases"
View More Articles